Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b

Affiliations

• ¹ Université de Paris, AP-HP, Hôpital Saint-Louis, Centre d'Investigations Cliniques, INSERM, CIC1427, Paris, France. jean-jacques.kiladjian@aphp.fr.
• ² AOP Orphan Pharmaceuticals, Vienna, Austria.
• ³ Medical University of Plovdiv, Plovdiv, Bulgaria.
• ⁴ Teaching Unit of the Hematology Department, University Hospital in Krakow, Krakow, Poland.
• ⁵ Clinical Hematology Clinic, Multiprofile Hospital for Active Treatment "Sveta Marina", Varna, Bulgaria.
• ⁶ Department of Internal Medicine II, Kaposi Mor County Teaching Hospital, Kaposvar, Hungary.
• ⁷ Department of Clinical Hematology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.
• ⁸ Department of Hematology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
• ⁹ Department of Hematology, Regional Treatment and Diagnostics Hematology Centre, Cherkasy Regional Oncology Centre, Cherkasy, Ukraine.
• ¹⁰ First Department of Internal Medicine, Multiprofile Hospital for Active Treatment - HristoBotev, Vratsa, Bulgaria.
• ¹¹ Clinic of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.
• ¹² Department of Hematology, Yaroslavl Regional Clinical Hospital, Yaroslavl, Russia.
• ¹³ Department of Hematology, Zealand University Hospital, Roskilde, University of Copenhagen, Copenhagen, Denmark.
• ¹⁴ Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
• ¹⁵ CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
• ¹⁶ Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University Vienna, Vienna, Austria.